Policy / Pricing Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain pharminent August 13, 2026
Policy / Pricing Trump signs order that nearly halves childhood immunisation coverage pharminent August 11, 2026
Policy / Pricing US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 pharminent July 22, 2026
Policy / Pricing Germany approves healthcare costs overhaul despite significant pharma opposition pharminent July 13, 2026
Policy / Pricing FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’ pharminent June 19, 2026
Policy / Pricing Medicare Part D Enrollment, Premiums, and Cost Sharing in 2026 pharminent June 11, 2026
Policy / Pricing How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market pharminent June 11, 2026
Policy / Pricing The next FDA commissioner must be a champion for gene therapies pharminent June 5, 2026
Policy / Pricing Stakeholders want Makary’s voucher program paused, call for FDA independence pharminent June 5, 2026
Policy / Pricing The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMs pharminent June 2, 2026
Policy / Pricing Hospital Prices Have Risen Much Faster for Private Insurance Than Medicare Since 2019 pharminent May 18, 2026
Policy / Pricing FDA’s leadership void leaves biotech with renewed ‘uncertainty’ pharminent May 13, 2026
Policy / Pricing UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged pharminent May 13, 2026
Policy / Pricing Makary resigns, with Diamantas named as acting FDA commissioner pharminent May 12, 2026
Policy / Pricing 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) pharminent May 12, 2026
Policy / Pricing What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge pharminent May 11, 2026
Policy / Pricing FDA Advances Drug Repurposing to Address Unmet Medical Needs pharminent May 11, 2026
Policy / Pricing Eligibility for Medicare Savings Programs for Specified Low-Income Medicare Beneficiaries (SLMBs) pharminent April 30, 2026
Policy / Pricing Eligibility for Medicare Savings Programs for Qualified Medicare Beneficiaries (QMBs) pharminent April 30, 2026
Policy / Pricing Eligibility for Medicare Savings Programs for Qualifying Individuals (QIs) pharminent April 30, 2026
Policy / Pricing Average Drug Fills and Average Gross Drug Costs Per Medicare Part D Enrollee pharminent April 30, 2026
Policy / Pricing Regeneron cuts White House pricing deal, offers new gene therapy for free pharminent April 24, 2026
Policy / Pricing CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices pharminent April 23, 2026
